StonvexLoading…
StonvexCore line items from NERV's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | Not available | $-21.85M | $-23.12M | $-25.23M | $-45.37M |
Net Income | Not available | $1.44M | $-30.01M | $-32.11M | $-49.91M |
EPS (Diluted) | $-0.12 | $0.19 | $-4.61 | $-6.01 | $-9.35 |
Total Assets | Not available | $37.14M | $56.90M | $55.09M | $77.12M |
Total Liabilities | Not available | $62.84M | $85.36M | $75.11M | $69.15M |
Cash & Equivalents | Not available | $21.36M | $40.91M | $36.09M | $60.76M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-24.66M | Not available |
Shares Outstanding | Not available | 6.99M | 6.99M | 5.34M | 5.34M |